Andrew Phimister

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 224 citations · Full text

Pathology, Farnesoid X Receptor, Pharmacotherapy +20

Developmental Exposure to Polychlorinated Biphenyls Interferes with Experience-Dependent Dendritic Plasticity and Ryanodine Receptor Expression in Weanling Rats

Dongren Yang, Kyung‐Ho Kim, Andrew Phimister et al. · Environmental Health Perspectives · 2008 · 163 citations · Full text

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

D. CHIANELLI, Paul V. Rucker, Jason Roland et al. · Journal of Medicinal Chemistry · 2020 · 97 citations · Full text

Conformation-dependent Stability of Junctophilin 1 (JP1) and Ryanodine Receptor Type 1 (RyR1) Channel Complex Is Mediated by Their Hyper-reactive Thiols

Andrew Phimister, József Langó, Eun Hui Lee et al. · Journal of Biological Chemistry · 2007 · 63 citations · Full text

Thiol Reactivity, Molecular Biology, Chemical Biology +21